Mr. Sarney has an MBA from Boston University and has spent more than 15 years working with biotechnology companies.
Avaxia Biologics is a biopharmaceutical company developing therapies for gastroenterological and inflammatory bowel disease applications.
More Articles on Gastroenterology:
NPS Pharmaceuticals’ Short Bowel Syndrome Treatment Shows Promise
RedHill Biopharma Seeks Patients for Phase III Crohn’s Disease Treatment Drug Trial
Kanawha Valley Gastroenterology Associates Selects Benchmark Systems EHR
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
